|Title||Lipoprotein-associated phospholipase A2 and venous thromboembolism: a prospective study.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Folsom AR, Lutsey PL, Roetker NS, Ballantyne CM, Hoogeveen RC, Rosamond WD|
|Secondary Authors||Cushman M|
|Corporate Authors||Atherosclerosis Risk in Communities(ARIC) study|
|Date Published||2013 Jul|
|Keywords||1-Alkyl-2-acetylglycerophosphocholine Esterase, Aged, Cholesterol, LDL, Female, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Venous Thromboembolism|
INTRODUCTION: Plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory marker associated positively with atherothrombotic risk. Whether Lp-PLA2 is related to risk of venous thromboembolism (VTE) is incompletely studied.
METHODS: We assessed Lp-PLA2 activity in 10,687 Atherosclerosis Risk in Communities (ARIC) Study participants and followed them a median of 8.3 years (from 1996-98 through 2005) for VTE occurrence (n=226).
RESULTS: There was no significant association between baseline Lp-PLA2 quartiles and risk of VTE, neither overall nor stratified as provoked or unprovoked. Adjusted for other risk factors, the hazard ratios (95% confidence interval) of total VTE across quartiles of Lp-PLA2 were 1.0 (reference), 0.95 (0.64, 1.42), 1.03 (0.69, 1.56), and 1.26 (0.83, 1.91). In the subset of participants with LDL-cholesterol ≥130 mg/dL, hazard ratios of total VTE were 1.00, 1.39 (0.44, 4.44), 2.45 (0.84, 7.11), and 2.84 (0.99, 8.14).
CONCLUSION: Our study does not support the overall hypothesis that elevated Lp-PLA2 contributes to VTE occurrence in the general population. However, in the presence of high LDL-cholesterol there was some evidence that Lp-PLA2 may increase VTE risk.
|Alternate Journal||Thromb Res|
|PubMed Central ID||PMC3742644|
|Grant List||HHSN268201100005C / / PHS HHS / United States |
R01 HL059367 / HL / NHLBI NIH HHS / United States
HHSN268201100009C / / PHS HHS / United States
R01 HL59367 / HL / NHLBI NIH HHS / United States
HHSN268201100010C / / PHS HHS / United States
N01 HC055019 / HC / NHLBI NIH HHS / United States
HHSN268201100008C / / PHS HHS / United States
HHSN268201100012C / / PHS HHS / United States
HHSN268201100007C / / PHS HHS / United States
HHSN268201100011C / / PHS HHS / United States
HHSN268201100006C / / PHS HHS / United States